Clinical Scorecard: Anti-VEGF Gains Ground in PDR
At a Glance
| Category | Detail |
|---|---|
| Condition | Proliferative Diabetic Retinopathy (PDR) |
| Key Mechanisms | Anti-VEGF therapy with brolucizumab vs. panretinal photocoagulation (PRP) |
| Target Population | Treatment-naïve patients with PDR |
| Care Setting | Clinical trial across multiple sites |
Key Highlights
- Brolucizumab showed a mean gain of 0.2 letters in BCVA compared to a decline of 4.2 letters with PRP.
- 63.6% of brolucizumab patients had no evidence of PDR at week 54 vs. 22.4% with PRP.
- Lower rates of CI-DME were observed with brolucizumab (31.1% vs 72.7%).
- Overall ocular adverse events were less frequent in the brolucizumab group (34.3% vs 49.1% with PRP).
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and disease status in patients with PDR.
Management
Monitoring & Follow-up
- Monitor for intraocular inflammation and other ocular adverse events in patients receiving brolucizumab.
Risks
- Be aware of potential adverse events including retinal vasculitis with brolucizumab.
Patient & Prescribing Data
Treatment-naïve patients with PDR
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
